Wearable health technology listings are testing investor appetite again as market volatility gives way to a busier autumn pipeline. Oura says it is targeting up to $2.2 billion in proceeds from its U.S. initial public offering, with demand indications from Eli Lilly and Dragoneer.
Highlights
- Oura and existing investors plan to sell 50 million shares at $40–$44 each, targeting up to $2.2 billion in the U.S. IPO.
- Eli Lilly expressed interest in purchasing up to $100 million and Dragoneer up to $300 million of Oura shares in the offering.
- Goldman Sachs, Morgan Stanley, and J.P. Morgan lead the underwriting for the Nasdaq listing under ticker symbol OURA.
IPO terms and investor backing
As reported by Reuters, Oura and some of its existing investors are looking to sell 50 million shares in the offering at between $40 and $44 each, according to a regulatory filing released on Monday.Weight-loss drugmaker Eli Lilly has indicated interest in purchasing up to $100 million of shares in the offering, while investment firm Dragoneer has indicated interest in buying up to $300 million worth of shares. The company says the transaction comes as the fall listing window starts to regain momentum after a subdued opening shaped by market swings.
Business profile and listing plan
Oura makes a smart ring that tracks health indicators including heart rate, sleep stages and physical activity, positioning the company in the wearable health technology segment.Goldman Sachs, Morgan Stanley and J.P. Morgan are the lead underwriters of the IPO. After the deal closes, Oura will list on the Nasdaq under the ticker symbol OURA.
In our earlier coverage of the Indian rupee’s trading outlook, we explained how IPO-linked foreign portfolio inflows were expected to help support the currency even as elevated crude oil prices added pressure. We also noted that the Reserve Bank of India’s policy tools and strong FX reserves were seen as key backstops keeping USD/INR in a relatively tight range.